Scientists find hidden drainage system at the back of the eye, upending a century of assumptions

Twenty minutes after researchers injected a tracer behind the retinas of mice, it showed up in lymph nodes in the neck. The fluid had traveled a route that, according to more than a century of scientific consensus, did not exist.

Scientists from the University of British Columbia and the University of Toronto have identified a previously unknown drainage pathway at the back of the eye — a system of tiny lymphatic vessels in the choroid, the blood vessel-rich layer beneath the retina, that carries fluid, waste proteins, and inflammatory material out of the eye and into the body's broader lymphatic network. They have named it the posterior ocular lymphatic outflow, or POLO pathway.

The study, published in Translational Vision Science & Technology, was conducted in mice. Whether the human eye follows the same design remains to be confirmed — but the researchers say the implications for understanding glaucoma, age-related macular degeneration, and other leading causes of permanent vision loss are immediate.

The retina is one of the most metabolically active parts of the body, constantly generating byproducts that need to be cleared. This discovery helps explain how the eye flushes this waste and promises to transform how we think about and treat a range of eye conditions.— Dr. Neeru Gupta, professor and head of ophthalmology and visual sciences, University of British Columbia

The lymphatic system — a network of thin-walled vessels that collect excess fluid, remove waste proteins, and deliver immune cells to lymph nodes — is present in nearly every organ in the body. For over a century, the eye was considered the exception. That assumption began to crack in 2009, when Gupta and Dr. Yeni Yücel, professor and director of ophthalmic pathology at the University of Toronto, identified a lymphatic-related drainage route at the front of the eye, which they named the uveolymphatic pathway. The back of the eye, where the retina sits and where most serious vision-loss diseases take hold, remained largely unexplored.

The retina is responsible for vision and it's also where many of the most serious vision-loss diseases occur. Understanding how this part of the eye maintains a balanced environment and flow of materials is critical.— Dr. Yeni Yücel, professor and director of ophthalmic pathology, University of Toronto

To find the POLO pathway, the team injected two types of tracer molecules into the suprachoroidal space — the thin gap between the eye's tough outer wall and the choroid — in anesthetized mice. One tracer was visible on MRI; the other glowed under near-infrared light, allowing the researchers to watch fluid move through a living eye in real time rather than reconstructing its path from tissue samples afterward.

The fluid did not disperse randomly. It consistently moved toward the nose-facing side of the eye socket, draining into surrounding orbital tissue and reaching a lymph node on the same side as the treated eye within 20 minutes. The treated side carried far more tracer signal than the other — a pattern inconsistent with random leakage.

Under a confocal microscope, the team found that choroidal vessels in these mice carried three proteins that appear together on lymphatic tissue and not on ordinary blood vessels — and that the injected tracer was present inside those same vessels. Earlier searches for lymphatic vessels in the choroid had come up empty, and the field had largely stopped looking. The combination of functional tracking and molecular markers is what transforms a suspicion into an identified pathway.

Because lymphatic vessels in the choroid were thought not to exist, the team used multiple techniques to demonstrate both their presence and function. We were surprised to see such a direct route for fluid to leave the eye and connect with the lymphatic system. It suggests the back of the eye has an active clearance pathway, which could play an important role in removing fluid, proteins and inflammatory material that build up in disease.— Dr. Yeni Yücel, pathologist-scientist, St. Michael's Hospital

The stakes are high. Glaucoma, age-related macular degeneration, and other retinal disorders are all associated with the buildup of fluid, metabolic waste, and inflammatory debris at the back of the eye. Age-related macular degeneration alone affects approximately 2.5 million Canadians, according to the research team. The POLO pathway offers a potential explanation for where that material is supposed to go — and, when the system falters, why it accumulates.

The retina's waste load is substantial. Light-sensing cells shed the worn tips of their structures every day; the layer of cells beneath them consumes the discards. Proteins leak from vessels. Immune cells leave debris. All of it must be cleared continuously for the retina to function. The POLO pathway, if it operates similarly in humans, would represent the primary exit route for this material from a region of the eye that medicine has long struggled to protect.

The discovery also carries practical implications for drug delivery. Eye clinics already inject therapeutics into the suprachoroidal space — the same entry point the researchers used. The new findings suggest that drugs placed there likely have an active exit route, which would affect how long they remain in the eye and where they travel in the body.

Gupta and Yücel had previously shown in a separate study that a common glaucoma eye drop increased lymphatic drainage from the eye in mice. Whether that effect operates through the newly mapped POLO pathway has not yet been tested, according to earth.com.

This gives us a whole new framework for understanding these diseases and a potential target for therapeutics. The question now is: How can we enhance or exploit this cleanup system to treat or even prevent disease.— Dr. Neeru Gupta, professor and head of ophthalmology and visual sciences, University of British Columbia

This is a foundational discovery that shows the eye is not as closed a system as we previously thought. It gives us a new map, a new mechanism and a new set of questions to explore.— Dr. Neeru Gupta, professor and head of ophthalmology and visual sciences, University of British Columbia

The next step is to determine whether the POLO pathway exists in human eyes. The 2009 uveolymphatic discovery at the front of the eye was subsequently confirmed in human tissue, which the researchers cite as reason to pursue the same confirmation at the back. If the pathway holds in humans, it becomes something clinicians can measure, target, and potentially restore — turning a century-old blind spot in eye science into a concrete object of study.

Why it matters — If the POLO pathway exists in humans as it does in mice, it would give researchers and clinicians a concrete, measurable target for treating glaucoma, macular degeneration, and other diseases that rob millions of their sight by letting waste accumulate where it was always supposed to drain.

Reported by sciencedaily.com, eurekalert.org, earth.com, science.org